Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.
Zagouri F, Terpos E, Fiste O, Liontos M, Briasoulis A, Katsiana I, Skafida E, Markellos C, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA. Zagouri F, et al. Among authors: markellos c. Breast. 2021 Dec;60:58-61. doi: 10.1016/j.breast.2021.08.017. Epub 2021 Aug 28. Breast. 2021. PMID: 34481366 Free PMC article.
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
Liontos M, Terpos E, Kunadis E, Zagouri F, Briasoulis A, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Gumeni S, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA. Liontos M, et al. Among authors: markellos c. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):117-118. doi: 10.1038/s41391-021-00455-9. Epub 2021 Oct 9. Prostate Cancer Prostatic Dis. 2022. PMID: 34628475 Free PMC article.
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.
Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA. Liontos M, et al. Among authors: markellos c. Vaccines (Basel). 2021 Oct 8;9(10):1148. doi: 10.3390/vaccines9101148. Vaccines (Basel). 2021. PMID: 34696256 Free PMC article.
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition.
Terpos E, Liontos M, Fiste O, Zagouri F, Briasoulis A, Sklirou AD, Markellos C, Skafida E, Papatheodoridi A, Andrikopoulou A, Koutsoukos K, Kaparelou M, Iconomidou VA, Trougakos IP, Dimopoulos MA. Terpos E, et al. Among authors: markellos c. Cancers (Basel). 2022 Jun 4;14(11):2796. doi: 10.3390/cancers14112796. Cancers (Basel). 2022. PMID: 35681774 Free PMC article.
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents.
Zagouri F, Papatheodoridi A, Liontos M, Briasoulis A, Sklirou AD, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Koutsoukos K, Kaparelou M, Gkogkou E, Trougakos IP, Dimopoulos MA, Terpos E. Zagouri F, et al. Among authors: markellos c. Vaccines (Basel). 2022 Sep 5;10(9):1474. doi: 10.3390/vaccines10091474. Vaccines (Basel). 2022. PMID: 36146552 Free PMC article.
Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit.
Liontos M, Kastritis E, Markellos C, Migkou M, Eleftherakis-Papaiakovou E, Koutsoukos K, Gavriatopoulou M, Zagouri F, Psaltopoulou T, Terpos E, Dimopoulos MA. Liontos M, et al. Among authors: markellos c. Cancers (Basel). 2021 Feb 12;13(4):763. doi: 10.3390/cancers13040763. Cancers (Basel). 2021. PMID: 33673120 Free PMC article.
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience.
Andrikopoulou A, Fiste O, Apostolidou K, Skafida E, Markellos C, Liontos M, Kyriazoglou A, Dimopoulos MA, Zagouri F. Andrikopoulou A, et al. Among authors: markellos c. Med Sci (Basel). 2021 Jun 5;9(2):42. doi: 10.3390/medsci9020042. Med Sci (Basel). 2021. PMID: 34198899 Free PMC article.
Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival.
Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos MA. Paschou SA, et al. Among authors: markellos c. Front Oncol. 2022 Mar 24;12:847917. doi: 10.3389/fonc.2022.847917. eCollection 2022. Front Oncol. 2022. PMID: 35402216 Free PMC article.
Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
Liontos M, Andrikopoulou A, Koutsoukos K, Markellos C, Skafida E, Fiste O, Kaparelou M, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F. Liontos M, et al. Among authors: markellos c. J Ovarian Res. 2021 Nov 1;14(1):148. doi: 10.1186/s13048-021-00902-0. J Ovarian Res. 2021. PMID: 34724958 Free PMC article.
14 results